Gamma Knife Market Size & Growth Forecast 2026–2035, By Segments (Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Gamma Knife Market size was around USD 486.03 Million in 2025 and is slated to grow at a 5.2% CAGR from 2026 to 2035, exceeding USD 806.9 Million by 2035. The industry revenue for 2026 is calculated at USD 507.91 million.

• Base Year Value (2025): USD 486.03 Million
• CAGR (2026-2035): 5.2%
• Forecast Year Value (2035): USD 806.9 Million
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Gamma Knife Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to advanced neurosurgical centers, strong imaging infrastructure, established radiosurgery workflows, and consistent procedural adoption for complex neurological and tumor cases.
  • Asia Pacific grows at 5.88% CAGR due to rising investment in specialized cancer and neurological care, expanding radiosurgery capacity, and growing adoption of non-invasive precision treatment systems.

• Segment Momentum:

  • Malignant tumors held a 48.44% market share in 2025, supported by sustained demand for precise intracranial treatment approaches that help control lesions while minimizing damage to surrounding brain tissue.
  • Benign tumors are growing fastest because clinicians increasingly favor highly targeted radiosurgery that preserves neurological function and reduces the procedural burden associated with open surgical interventions.

• Market Expansion Drivers:

  • Rising prevalence of brain tumors increasing demand for precision radiosurgery treatments.
  • Technological advancements in frameless gamma knife systems improving treatment precision and workflow efficiency.
  • Expanding minimally invasive neurosurgery adoption strengthening hospital investments in advanced radiotherapy platforms.

• Leading Market Participants:

  Leading players in the gamma knife market include Elekta AB (Sweden), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (United States), Varian Medical Systems, Inc. (United States), Huiheng Medical, Inc. (China), Masep Medical Science & Technology Development Co., Ltd. (China), Accuray Incorporated (United States), Brainlab AG (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 486.03 Million
  • Projected Market Size: USD 806.9 Million by 2035
  • Growth Forecasts: 5.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Malignant Tumors (Indication)
  • Emerging Opportunity Segment: Benign Tumors (Indication)

Market Growth Drivers and Industry Trends

Rising prevalence of brain tumors increasing demand for precision radiosurgery treatments

A growing brain tumor patient pool is shifting treatment decision-making toward modalities that can target intracranial lesions with high accuracy while avoiding the morbidity associated with open surgery, and that dynamic is driving demand for the gamma knife market. As clinicians manage more cases involving difficult-to-access tumors, recurrent lesions, and patients who are poor surgical candidates, precision radiosurgery becomes a practical pathway because it fits multidisciplinary neuro-oncology care and supports treatment planning around tumor location, size, and surrounding critical structures. This is increasing market penetration for dedicated gamma knife systems in centers seeking to handle more complex cranial caseloads with a specialized platform rather than relying solely on conventional radiotherapy equipment.

Technological advancements in frameless gamma knife systems improving treatment precision and workflow efficiency

Frameless system innovation is influencing market adoption by removing one of the main operational and patient-experience barriers historically associated with gamma knife procedures. When immobilization, imaging integration, and targeting software improve to support highly precise treatment without invasive head frame placement in every case, providers can expand eligibility, streamline scheduling, and reduce friction in referral conversion for the gamma knife market. Workflow efficiency also matters commercially: hospitals and specialty centers are more willing to invest when a platform can support smoother treatment throughput, better staff utilization, and stronger alignment with modern image-guided radiosurgery protocols.

Expanding minimally invasive neurosurgery adoption strengthening hospital investments in advanced radiotherapy platforms

As neurosurgery increasingly favors less invasive intervention pathways, hospitals are reassessing capital allocation toward technologies that complement that care model, which is supporting market expansion for the gamma knife market. Gamma knife systems fit this strategic shift because they offer a non-incisional option for selected cranial conditions, allowing providers to broaden treatment portfolios while reducing dependence on procedures that require more operating room resources, longer recovery periods, or higher perioperative burden. This is supporting market development through hospital investment decisions tied not only to clinical capability, but also to service-line differentiation, referral retention, and the ability to position comprehensive brain care around minimally invasive treatment pathways.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of brain tumors increasing demand for precision radiosurgery treatments	2.00%	Moderate	North America, Europe, Asia Pacific	High	Near Term
Technological advancements in frameless gamma knife systems improving treatment precision and workflow efficiency	1.80%	High	North America, Europe	High	Mid Term
Expanding minimally invasive neurosurgery adoption strengthening hospital investments in advanced radiotherapy platforms	1.50%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the gamma knife market, supported by the concentration of advanced neurosurgical centers, established referral pathways for intracranial tumor and functional disorder treatment, and broad access to high-value imaging and radiation planning infrastructure. The region’s leadership is strengthened by routine integration of stereotactic radiosurgery into clinical practice, where hospitals and specialty centers can maintain patient volumes, multidisciplinary decision-making, and reimbursement-supported use for complex neurological cases. This operating environment helps sustain demand for system upgrades, treatment planning capabilities, and ongoing procedural utilization.

Asia Pacific is projected to expand at a 5.88% CAGR over the forecast period, with growth in the gamma knife market being propelled by rising investment in specialized cancer and neurological care capacity across major healthcare systems. Adoption is accelerating as more providers build radiosurgery capabilities to manage growing case volumes while reducing the need for invasive cranial procedures, particularly in large urban treatment networks. The region’s momentum also reflects improving access to advanced hospital infrastructure and increasing willingness among providers to deploy precision treatment platforms where clinical throughput and non-invasive care delivery are becoming more important.

Key Country Insights

United States

Advanced Neurosurgical Care

The U.S. maintains demand for Gamma Knife systems through specialized neurosurgical centers treating complex brain disorders. Healthcare providers prioritize workflow efficiency, treatment precision, and integration with advanced imaging technologies to support minimally invasive neurological care.

Japan

High-Accuracy Treatment Pathways

Japan applies Gamma Knife technology to support precise treatment of neurological conditions while minimizing invasive procedures. Japanese hospitals prioritize equipment reliability, advanced treatment planning, and efficient patient management within established neurosurgical care pathways.

South Korea

Specialized Treatment Expansion

South Korea continues expanding access to Gamma Knife procedures through advanced tertiary hospitals and specialized neurological care centers. Healthcare providers focus on integrating precise radiosurgery with modern imaging technologies and coordinated patient treatment pathways.

Germany

Precision Radiosurgery Services

Germany emphasizes Gamma Knife utilization within specialized neuroscience centers that focus on highly accurate intracranial treatment. German healthcare providers continue investing in advanced radiosurgery capabilities that improve clinical planning, patient outcomes, and multidisciplinary treatment coordination.

France

Multidisciplinary Neuroscience Focus

France strengthens Gamma Knife utilization through multidisciplinary clinical teams managing complex intracranial disorders. French hospitals emphasize precise treatment planning, technology modernization, and coordinated care that supports effective radiosurgical interventions for eligible patients.

Italy

Hospital Technology Renewal

Italy advances Gamma Knife adoption by upgrading neurosurgical treatment capabilities within specialized healthcare facilities. Italian providers prioritize modern radiosurgery platforms that improve procedural efficiency, support accurate treatment delivery, and enhance collaboration across neurological care teams.

Segment Leadership and Growth Trends

  Indication Segment Analysis: Malignant Tumors (Largest Segment) vs Benign Tumors (Fastest-Growing Segment)

Malignant tumors held a 48.44% share of the gamma knife market in 2025, making this the leading indication segment. its position is anchored in the sustained clinical use of gamma knife systems for precise intracranial treatment where lesion control must be achieved while limiting damage to surrounding brain tissue. The segment’s large share also reflects the practical treatment demand associated with complex malignant cases, where non-invasive or minimally disruptive radiosurgical approaches are often prioritized within neuro-oncology care pathways.

Benign tumors are the fastest-growing indication in the gamma knife market as treatment decisions increasingly favor highly targeted radiosurgery for lesions located near critical brain structures. Growth in this segment is being backed by the need to preserve neurological function while avoiding the risks and recovery burden associated with open procedures. Compared with alternatives that may involve greater procedural disruption, gamma knife treatment is gaining momentum for benign tumors because it aligns well with the clinical requirement for precision, tissue sparing, and patient management efficiency.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Indication	Malignant Tumors, Benign Tumors, Vascular Disorders, Functional Disorders, Ocular Diseases	Malignant Tumors	Benign Tumors

Competitive Landscape and Market Positioning

Key companies in the gamma knife market:

1. Elekta AB (Sweden)

2. Siemens Healthineers AG (Germany)

3. GE HealthCare Technologies Inc. (United States)

4. Varian Medical Systems Inc. (United States)

5. Huiheng Medical Inc. (China)

6. Masep Medical Science & Technology Development Co. Ltd. (China)

7. Accuray Incorporated (United States)

8. Brainlab AG (Germany)

Technological progress in precision radiosurgery is shaping the competitive environment of the gamma knife market. Industry participants are introducing advanced treatment planning systems, improved imaging integration, and enhanced targeting capabilities to support more accurate neurological procedures. Expansion into emerging healthcare facilities and increasing emphasis on non-invasive treatment alternatives are also contributing to broader adoption and competitive differentiation within the market.

Industry Development/News

Company Name	Date	Key Development
Health Sciences Centre Winnipeg	Mar-26	The Health Sciences Centre Winnipeg integrated a next-generation Gamma Knife stereotactic radiosurgery system into its neurosurgical department. This deployment enhances the facility's capacity for minimally invasive brain treatments, directly expanding high-precision neurological care and radiosurgery capabilities within the Manitoba healthcare region.
Ram Manohar Lohia Institute of Medical Sciences	Oct-25	The institute inaugurated the first Gamma Knife center in Uttar Pradesh, marking a significant expansion of non-invasive neurosurgical infrastructure. The facility provides specialized radiosurgery for complex brain tumors and neurological disorders, effectively increasing the regional availability of precision-targeted radiation therapy.
KIMS Hospital	May-25	KIMS Hospital expanded its neuro-oncology service line by commissioning advanced Gamma Knife stereotactic radiosurgery capabilities. The move strengthens the hospital's position in the precision oncology market by offering a non-invasive treatment pathway for brain disorders, improving patient access to specialized neurological care.
Fortis Memorial Research Institute	Jun-24	The institute launched South Asia’s first Gamma Knife Esprit system, upgrading its radiotherapy infrastructure for complex neurological and oncological interventions. This deployment represents a major advancement in regional radiosurgery capacity, enabling more precise, incision-free treatment for patients with brain-based pathologies.
AdventHealth Orlando	Jun-24	AdventHealth Orlando completed the deployment of the Gamma Knife Elekta Esprit platform. This strategic technology integration enhances the center’s radiosurgery portfolio, allowing for more efficient treatment of intracranial tumors and neurological conditions through the application of advanced, incision-free radiation delivery technology.
Atrium Health	Jul-24	Atrium Health recorded rapid clinical adoption of its Gamma Knife radiosurgery program, exceeding 100 procedures within five months of operational launch. This milestone validates the market demand for specialized stereotactic radiosurgery services and demonstrates the effective scaling of advanced neurosurgical technology within a large-scale hospital network.